Bristol beats forecasts as cancer, blood clot drugs deliver

October 27, 2015 11:10 AM

28 0

Oct 27 Bristol-Myers Squibb Co reported better than expected quarterly earnings, fueled by surging sales of its recently approved Opdivo immuno-oncology drug, hepatitis C treatments and its Eliquis blood clot preventer.

The company said it earned $706 million, or 42 cents per share, in the third quarter. That compared with $721 million, or 43 cents per share, in the year-earlier period.

Also read: Philip Morris Stock Sees Worst Day in a Decade on Declining Cigarette Volume

Read more

To category page